CA
NZ
UK
AU
IND
US
● Scilex amended its revolving line ofCreditto Vivasor, raising the maximum amount under the note from $20,000,000 to $30,000,000.
● Aldeyra intends to file a Formal Dispute Resolution Request with the FDA in the fourth quarter of 2026.
● A prospective study of Renuvion in patients undergoing facelift surgery was published in Plastic and Reconstructive Surgery Global Open.
● Moleculin completed enrollment of Part A of its MIRACLE trial, with 89 subjects enrolled and one more in screening.
● uniQure furnished a September 29, 2026 8-K with 36-month and 48-month follow-up for AMT-130, its Huntington's disease gene therapy.
● Five patients with generalized myasthenia gravis were retreated with Descartes-08 at a median of 16.6 months after initial treatment.
● Summit will issue 108,955.3686 shares of Class A Convertible Preferred Stock at $18,356.14 each, for $2.0 billion in gross proceeds.
● AstraZeneca will invest $2 billion in newly issued Summit securities, structured as approximately 109,000 shares of convertible preferred stock.
● Dyne reported that hand-opening time improved by 3.2 seconds at six months in the pooled group, while placebo worsened.
● Immix reported that 40 of 45 patients, or 89 percent, achieved a complete response in NEXICART-2, per independent review.
Please wait processing your request...